RDY Current Deferred Revenue from 2010 to 2024
| RDY Stock | USD 74.42 0.13 0.17% |
Current Deferred Revenue | First Reported 2001-06-30 | Previous Quarter 3 B | Current Value 2.3 B | Quarterly Volatility 25 B |
Check Dr Reddys financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RDY main balance sheet or income statement drivers, such as Interest Expense of 1.7 B, Total Revenue of 296.9 B or Gross Profit of 245.1 B, as well as many exotic indicators such as Price To Sales Ratio of 3.48, Dividend Yield of 0.0055 or PTB Ratio of 4.2. RDY financial statements analysis is a perfect complement when working with Dr Reddys Valuation or Volatility modules.
RDY | Current Deferred Revenue |
Latest Dr Reddys' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Dr Reddys Laboratories over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Dr Reddys' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dr Reddys' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
RDY Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 1,233,045,276 | |
| Geometric Mean | 912,387,370 | |
| Coefficient Of Variation | 59.38 | |
| Mean Deviation | 626,178,409 | |
| Median | 1,056,000,000 | |
| Standard Deviation | 732,194,064 | |
| Sample Variance | 536108.1T | |
| Range | 2.5B | |
| R-Value | 0.88 | |
| Mean Square Error | 130226.7T | |
| R-Squared | 0.77 | |
| Significance | 0.000015 | |
| Slope | 144,080,414 | |
| Total Sum of Squares | 7505514.1T |
RDY Current Deferred Revenue History
About Dr Reddys Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Dr Reddys income statement, its balance sheet, and the statement of cash flows. Dr Reddys investors use historical funamental indicators, such as Dr Reddys's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Dr Reddys investors may use each financial statement separately, they are all related. The changes in Dr Reddys's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Dr Reddys's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Dr Reddys Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Dr Reddys. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.8 B | 1.7 B |
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out the analysis of Dr Reddys Correlation against competitors. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.76 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.